Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 92 articles:
HTML format
Text format



Single Articles


    October 2017
  1. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    September 2017
  2. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Text format     Abstract available


  3. PONZETTI M, Capulli M, Angelucci A, Ventura L, et al
    Non-conventional role of haemoglobin beta in breast malignancy.
    Br J Cancer. 2017;117:994-1006.
    PubMed     Text format     Abstract available


  4. MORRELL S, Roder D, Taylor R
    Reply to 'Comment on 'Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study''.
    Br J Cancer. 2017 Sep 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  5. GREGOIRE C, Bragard I, Jerusalem G, Etienne AM, et al
    Group interventions to reduce emotional distress and fatigue in breast cancer patients: a 9-month follow-up pragmatic trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  6. YE ZJ, Qiu HZ, Liang MZ, Liu ML, et al
    Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  7. OSAKO T, Iwase T, Ushijima M, Yonekura R, et al
    A new molecular-based lymph node staging classification determines the prognosis of breast cancer patients.
    Br J Cancer. 2017 Sep 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  8. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    PubMed     Text format     Abstract available


    August 2017
  9. CAPELAN M, Battisti NML, McLoughlin A, Maidens V, et al
    The prevalence of unmet needs in 625 women living beyond a diagnosis of early breast cancer.
    Br J Cancer. 2017 Aug 31. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  10. GURVITS N, Loyttyniemi E, Nykanen M, Kuopio T, et al
    Separase is a marker for prognosis and mitotic activity in breast cancer.
    Br J Cancer. 2017 Aug 31. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  11. ALESKANDARANY MA, Sonbul S, Surridge R, Mukherjee A, et al
    Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.
    Br J Cancer. 2017 Aug 22. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  12. OKONJI DO, Sinha R, Phillips I, Fatz D, et al
    Comprehensive geriatric assessment in 326 older women with early breast cancer.
    Br J Cancer. 2017 Aug 10. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  13. SHI F, Zhang Q, Liang Z, Zhang M, et al
    One-step nucleic acid amplification assay is an accurate technique for sentinel lymph node biopsy of breast cancer patients: a meta-analysis.
    Br J Cancer. 2017 Aug 10. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  14. SHARMA R, Huang X, Brekken RA, Schroit AJ, et al
    Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.
    Br J Cancer. 2017;117:545-552.
    PubMed     Text format     Abstract available


    July 2017
  15. SMITH A, Murphy L, Zgaga L, Barron TI, et al
    Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer.
    Br J Cancer. 2017 Jul 18. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  16. JIANG L, Luan Y, Miao X, Sun C, et al
    Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling.
    Br J Cancer. 2017 Jul 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  17. VAN MAAREN MC, Bretveld RW, Jobsen JJ, Veenstra RK, et al
    The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival.
    Br J Cancer. 2017;117:179-188.
    PubMed     Text format     Abstract available


  18. WU J, Zhou XJ, Sun X, Xia TS, et al
    RBM38 is involved in TGF-beta-induced epithelial-to-mesenchymal transition by stabilising zonula occludens-1 mRNA in breast cancer.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    June 2017
  19. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Text format     Abstract available


  20. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Text format     Abstract available


  21. PEDERSEN AB, Horvath-Puho E, Ehrenstein V, Rorth M, et al
    Frozen shoulder and risk of cancer: a population-based cohort study.
    Br J Cancer. 2017;117:144-147.
    PubMed     Text format     Abstract available


  22. MAVROUDIS D, Saloustros E, Boukovinas I, Papakotoulas P, et al
    Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  23. LEVASSEUR N, Chia SK
    Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  24. MOSKOWITZ CS, Chou JF, Sklar CA, Barnea D, et al
    Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  25. CUI YX, Bradbury R, Flamini V, Wu B, et al
    MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells.
    Br J Cancer. 2017 Jun 1. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  26. CHEN LL, Zhang ZJ, Yi ZB, Li JJ, et al
    MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Br J Cancer. 2017 Jun 1. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    May 2017
  27. PAPADAKIS ES, Reeves T, Robson NH, Maishman T, et al
    BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses.
    Br J Cancer. 2017 May 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    April 2017
  28. HEQUET D, Huchon C, Baffert S, Alran S, et al
    Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators.
    Br J Cancer. 2017 Apr 25. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  29. KWIATKOWSKI F, Mouret-Reynier MA, Duclos M, Bridon F, et al
    Long-term improvement of breast cancer survivors' quality of life by a 2-week group physical and educational intervention: 5-year update of the 'PACThe' trial.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  30. ROMAN M, Quintana MJ, Ferrer J, Sala M, et al
    Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer: supporting personalised screening.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  31. TRAN WT, Gangeh MJ, Sannachi L, Chin L, et al
    Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis.
    Br J Cancer. 2017 Apr 18. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  32. MESCI A, Huang X, Taeb S, Jahangiri S, et al
    Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis.
    Br J Cancer. 2017 Apr 18. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  33. MILLER AB
    Comment on 'Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study'.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Text format    


    March 2017
  34. CHIARELLI AM, Muradali D, Blackmore KM, Smith CR, et al
    Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  35. TRUDEL-FITZGERALD C, Zhou ES, Poole EM, Zhang X, et al
    Sleep and survival among women with breast cancer: 30 years of follow-up within the Nurses' Health Study.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  36. SHEN J, Liao Y, Hopper JL, Goldberg M, et al
    Dependence of cancer risk from environmental exposures on underlying genetic susceptibility: an illustration with polycyclic aromatic hydrocarbons and breast cancer.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  37. MANDL MM, Zhang S, Ulrich M, Schmoeckel E, et al
    Inhibition of Cdk5 induces cell death of tumor-initiating cells.
    Br J Cancer. 2017;116:912-922.
    PubMed     Text format     Abstract available


  38. BEGG CB, Rice MS, Zabor EC, Tworoger SS, et al
    Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  39. ROUZIER R, Uzan C, Rousseau A, Guillot E, et al
    Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NO
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  40. ALTUNDAG K
    Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'.
    Br J Cancer. 2017 Mar 14. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  41. FUJII T, Ueno NT
    Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''.
    Br J Cancer. 2017 Mar 14. doi: 10.1038/bjc.2017.
    PubMed     Text format    


    February 2017
  42. BRESLIN S, Lowry MC, O'Driscoll L
    Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.
    Br J Cancer. 2017;116:620-625.
    PubMed     Text format     Abstract available


  43. PINDER SE, Campbell AF, Bartlett JM, Marshall A, et al
    Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.
    Br J Cancer. 2017 Feb 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  44. CATALANO OA, Horn GL, Signore A, Iannace C, et al
    PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  45. PARK YM, O'Brien KM, Zhao S, Weinberg CR, et al
    Gestational diabetes mellitus may be associated with increased risk of breast cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  46. YIP C, Foidart P, Somja J, Truong A, et al
    MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
    Br J Cancer. 2017 Feb 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  47. MORRELL S, Taylor R, Roder D, Robson B, et al
    Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011.
    Br J Cancer. 2017 Feb 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  48. MOYNAHAN ME, Chen D, He W, Sung P, et al
    Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.
    Br J Cancer. 2017 Feb 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  49. DE PLACIDO S, De Angelis C, Giuliano M, Pizzi C, et al
    Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.
    Br J Cancer. 2017 Feb 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  50. HANSEN MF, Jensen SO, Fuchtbauer EM, Martensen PM, et al
    High folic acid diet enhances tumour growth in PyMT-induced breast cancer.
    Br J Cancer. 2017 Feb 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  51. BOUCHARD G, Therriault H, Geha S, Bujold R, et al
    Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  52. FUJII T, Kogawa T, Wu J, Sahin AA, et al
    Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Br J Cancer. 2017 Jan 12. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  53. KAZARIAN A, Blyuss O, Metodieva G, Gentry-Maharaj A, et al
    Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.
    Br J Cancer. 2017 Jan 12. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  54. PARRA K, Valenzuela P, Lerma N, Gallegos A, et al
    Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.
    Br J Cancer. 2017 Jan 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  55. ROCHEFORT P, Chabaud S, Pierga JY, Tredan O, et al
    Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.
    Br J Cancer. 2017 Jan 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  56. SOOD D, Johnson N, Jain P, Siskos AP, et al
    CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites.
    Br J Cancer. 2017;116:382-388.
    PubMed     Text format     Abstract available


    December 2016
  57. COOK LS, Pestak CR, Leung AC, Steed H, et al
    Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  58. JOHNS LE, Coleman DA, Swerdlow AJ, Moss SM, et al
    Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study.
    Br J Cancer. 2016 Dec 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  59. UUSITALO E, Kallionpaa RA, Kurki S, Rantanen M, et al
    Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors.
    Br J Cancer. 2016 Dec 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  60. DALDORFF S, Mathiesen RM, Yri OE, Odegard HP, et al
    Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.
    Br J Cancer. 2016 Dec 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  61. SUN J, Chia S
    Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  62. LAMBERTINI M, Pinto AC, Ameye L, Jongen L, et al
    The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.
    Br J Cancer. 2016 Nov 1. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  63. MOLLER H, Henson K, Luchtenborg M, Broggio J, et al
    Short-term breast cancer survival in relation to ethnicity, stage, grade and receptor status: national cohort study in England.
    Br J Cancer. 2016 Oct 25. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  64. ZAAIJER LH, van Doorn HC, Mourits MJ, van Beurden M, et al
    Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2016 Oct 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  65. LAM SW, Frederiks CN, van der Straaten T, Honkoop AH, et al
    Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  66. OBIORAH I, Sengupta S, Fan P, Jordan VC, et al
    Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  67. COLZANI E, Clements M, Johansson AL, Liljegren A, et al
    Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  68. HOUVENAEGHEL G, Sabatier R, Reyal F, Classe JM, et al
    Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
    Br J Cancer. 2016 Sep 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  69. CAMPBELL EJ, Tesson M, Doogan F, Mohammed ZM, et al
    The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  70. TONETTI DA, Chisamore MJ, Grdina W, Schurz H, et al
    Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  71. LIM E, Palmieri C, Tilley WD
    Renewed interest in the progesterone receptor in breast cancer.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  72. PRESTON DL, Kitahara CM, Freedman DM, Sigurdson AJ, et al
    Breast cancer risk and protracted low-to-moderate dose occupational radiation exposure in the US Radiologic Technologists Cohort, 1983-2008.
    Br J Cancer. 2016 Sep 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  73. BOSCO-LEVY P, Jove J, Robinson P, Moore N, et al
    Persistence to 5-year hormonal breast cancer therapy: a French national population-based study.
    Br J Cancer. 2016 Sep 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  74. JONASSON JG, Stefansson OA, Johannsson OT, Sigurdsson H, et al
    Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  75. DE MUNCK L, de Bock GH, Otter R, Reiding D, et al
    Digital vs screen-film mammography in population-based breast cancer screening: performance indicators and tumour characteristics of screen-detected and interval cancers.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  76. SMITH A, Murphy L, Sharp L, O'Connor D, et al
    De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.
    Br J Cancer. 2016 Aug 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    July 2016
  77. JONES ME, Schoemaker MJ, Wright L, McFadden E, et al
    Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
    Br J Cancer. 2016 Jul 28. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  78. ZHU B, Mukherjee A, Machiela MJ, Song L, et al
    An investigation of the association of genetic susceptibility risk with somatic mutation burden in breast cancer.
    Br J Cancer. 2016 Jul 28. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    June 2016
  79. MILLICAN-SLATER RA, Sayers CD, Hanby AM, Hughes TA, et al
    Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  80. PERSSON M, Simonsson M, Markkula A, Rose C, et al
    Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  81. GRAM IT, Little MA, Lund E, Braaten T, et al
    The fraction of breast cancer attributable to smoking: The Norwegian women and cancer study 1991-2012.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  82. SOGAARD M, Farkas DK, Ording AG, Sorensen HT, et al
    Conisation as a marker of persistent human papilloma virus infection and risk of breast cancer.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    May 2016
  83. DREW Y, Ledermann J, Hall G, Rea D, et al
    Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Br J Cancer. 2016 May 26. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  84. MELVIN JC, Purushotham AD, Garmo H, Pinder SE, et al
    Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time.
    Br J Cancer. 2016 May 26. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  85. WARSCHKOW R, Cerny T, Schmied BM, Guller U, et al
    A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction.
    Br J Cancer. 2016 May 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  86. MESEURE D, Vacher S, Lallemand F, Alsibai KD, et al
    Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer.
    Br J Cancer. 2016 May 12. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    March 2016
  87. BROWN JS, Kaye SB, Yap TA
    PARP inhibitors: the race is on.
    Br J Cancer. 2016;114:713-5.
    PubMed     Text format    


  88. RATNER ES, Zhu YL, Penketh PG, Berenblum J, et al
    Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
    Br J Cancer. 2016;114:777-86.
    PubMed     Text format     Abstract available


  89. PHI XA, Saadatmand S, De Bock GH, Warner E, et al
    Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
    Br J Cancer. 2016;114:631-7.
    PubMed     Text format     Abstract available


  90. LOUSDAL ML, Kristiansen IS, Moller B, Stovring H, et al
    Effect of organised mammography screening on stage-specific incidence in Norway: population study.
    Br J Cancer. 2016;114:590-6.
    PubMed     Text format     Abstract available


    February 2016
  91. THOMSON AH, McGrane J, Mathew J, Palmer J, et al
    Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes.
    Br J Cancer. 2016 Feb 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    January 2016
  92. HAMY-PETIT AS, Belin L, Bonsang-Kitzis H, Paquet C, et al
    Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.
    Br J Cancer. 2016;114:44-52.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: